Cargando…
Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy
Oncolytic viral immunotherapies are agents which can directly kill tumor cells and activate an immune response. Oncolytic viruses (OVs) range from native/unmodified viruses to genetically modified, attenuated viruses with the capacity to preferentially replicate in and kill tumors, leaving normal ti...
Autores principales: | Robilotti, Elizabeth, Zeitouni, Nathalie C., Orloff, Marlana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546393/ https://www.ncbi.nlm.nih.gov/pubmed/37795219 http://dx.doi.org/10.3389/fmolb.2023.1178382 |
Ejemplares similares
-
Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability
por: Howard, Faith, et al.
Publicado: (2022) -
Biosafety and Biohazards: Understanding Biosafety Levels and Meeting Safety Requirements of a Biobank
por: Ta, Lisa, et al.
Publicado: (2018) -
Editorial: Oncolytic virotherapy
por: Al-Shammari, Ahmed Majeed, et al.
Publicado: (2023) -
HSV: The scout and assault for digestive system tumors
por: Li, Sheng, et al.
Publicado: (2023) -
Utility of a Recombinant HSV-1 Vaccine Vector for Personalized Cancer Vaccines
por: Uche, Ifeanyi Kingsley, et al.
Publicado: (2022)